NCT07364708 AC Deflation in Descemet's Membrane Detachment
| NCT ID | NCT07364708 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Minia University |
| Condition | Descemet's Membrane Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-07-20 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-07-20 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
using a relatively new technique to manage post-cataract surgery complication and measuring its efficacy
Eligibility Criteria
Inclusion Criteria: * Patients with post cataract surgery DM detachment diagnosed within 1st week postoperatively. * Patient age ranges from 50 to 70 years old. Exclusion Criteria: * Less than one third of Descemet's Membrane is included. * Post-operative infection or severe inflammation. * Patient with pre-existing glaucoma.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07364708 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Descemet's Membrane Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07364708 currently recruiting?
Yes, NCT07364708 is actively recruiting participants. Contact the research team at drahmedmaher1988@gmail.com for enrollment information.
Where is the NCT07364708 trial being conducted?
This trial is being conducted at Minya, Egypt.
Who is sponsoring the NCT07364708 clinical trial?
NCT07364708 is sponsored by Minia University. The trial plans to enroll 50 participants.